Neurogene, a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the completion of a $115m Series B financing.
Neurogene announces that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to its adeno-associated virus vector (AAV) with engineered transgene encoding the human AGA gene for patients diagnosed with aspartylglucosaminuria.
Neurogene has secured funding during a Series A financing round to advance the development of its gene therapy candidates intended for the treatment of various neurological diseases....